The Interaction of Botrocetin with Normal or Variant von Willebrand Factor (Types IIA and IIB) and Its Inhibition by Monoclonal Antibodies that Block Receptor Binding

Y Fujimura; S Miyata; S Nishida; S Miura; M Kaneda; A Yoshioka; H Fukui; M Katayama; E G D Tuddenham; Y Usami; K Titani

doi:10.1055/s-0038-1646298

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1992; 68(04): 464-469
DOI: 10.1055/s-0038-1646298

Original Article

Schattauer GmbH Stuttgart

The Interaction of Botrocetin with Normal or Variant von Willebrand Factor (Types IIA and IIB) and Its Inhibition by Monoclonal Antibodies that Block Receptor Binding

Y Fujimura

¹The Departments of Blood Transfusion and Pediatrics, Nara Medical College, Kashihara, Nara, Japan

,

S Miyata

¹The Departments of Blood Transfusion and Pediatrics, Nara Medical College, Kashihara, Nara, Japan

,

S Nishida

¹The Departments of Blood Transfusion and Pediatrics, Nara Medical College, Kashihara, Nara, Japan

,

S Miura

¹The Departments of Blood Transfusion and Pediatrics, Nara Medical College, Kashihara, Nara, Japan

,

M Kaneda

¹The Departments of Blood Transfusion and Pediatrics, Nara Medical College, Kashihara, Nara, Japan

,

A Yoshioka

¹The Departments of Blood Transfusion and Pediatrics, Nara Medical College, Kashihara, Nara, Japan

,

H Fukui

¹The Departments of Blood Transfusion and Pediatrics, Nara Medical College, Kashihara, Nara, Japan

,

M Katayama

²The Takara-Shuzo Co, Ohtsu, Shiga, Japan

,

E G D Tuddenham

³The Clinical Research Centre, Middlesex, U. K.

,

Y Usami

⁴The Division of Biomedical Polymer Science, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

,

K Titani

⁴The Division of Biomedical Polymer Science, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

› Institutsangaben

Abstract

als PDF herunterladen

Summary

We have recently shown the existence of two distinct forms of botrocetin (one-chain and two-chain), and demonstrated that the two-chain species is approximately 30 times more active than the one-chain in promoting von Willebrand factor (vWF) binding to platelet glycoprotein (GP) Ib. The N-terminal sequence of two-chain botrocetin is highly homologous to sea-urchin Echinoidin and other Ca²⁺-dependent lectins (Fujimura et al., Biochemistry 1991; 30: 1957–64).

Present data indicate that purified two-chain botrocetin binds to vWF from plasmas of patients with type IIA or IIB von Willebrand disease and its interaction is indistinguishable from that with vWF from normal individuals. However, an “activated complex” formed between botrocetin and IIB vWF expresses an enhanced biological activity for binding to GP Ib whereas the complex with IIA vWF has a decreased binding activity. Among several anti-vWF monoclonal antibodies (MoAbs) which inhibit ristocetin-induced platelet aggregation and/or vWF binding to GPIb, only two MoAbs (NMC-4 and RFF-VIII RAG:1) abolished direct binding between purified botrocetin and vWF. This suggests that they recognize an epitope(s) on the vWF molecule in close proximity to the botrocetin binding site.

PDF (1751 kb)

Referenzen

REFERENCES
1 Girma J-P, Meyer D, Verweij CL, Pannekoek H, Sixma JJ. Structure-function relationship of human von Willebrand factor. Blood 1987; 70: 605-611
2 Coller BS, Gralnick HR. Studies on the mechanism of ristocetin-induced platelet agglutination; effects of structural modification of ristocetin and vancomycin. J Clin Invest 1977; : 302-312
3 Philip JE, Schenck JR, Hargie MP. Ristocetins A and B, two new antibiotics; Isolation and properties. Antibiotics Annual 1956; 1957; pp 699-705
4 Fehlner JR, Hutchinson REJ, Tarbell DS, Schenck JR. Structure of ristocetin A. Proc Natl Acad Sci USA 1972; 69: 2420-2421
5 Read MS, Shermer RW, Brinkhous KM. Venom coagglutinin: an activator of platelet aggregation dependent on von Willebrand factor. Proc Natl Acad Sci USA 1978; 75: 4514-4518
6 Brinkhous KM, Read MS, Fricke WA, Wagner RH. Botrocetin (venom coagglutinin): reaction with a broad spectrum of multimeric forms of factor VIII macromolecular complex. Proc Natl Acad Sci USA 1983; 80: 1463-1466
7 Read MS, Smith SV, Lamb MA, Brinkhous KM. Role of botrocetin in platelet agglutination: formation of an activated complex of botrocetin and von Willebrand factor. Blood 1989; 7: 1031-1035
8 Andrews RK, Booth WJ, Gorman JJ, Castaldi PA, Berndt MC. Purification of botrocetin from Bothrops jararaca venom. Analysis of the botrocetin-mediated interaction between von Willebrand factor and the human platelet membrane glycoprotein Ib-IX complex. Biochemistry. 1989; 28: 8317-8326
9 Fujimura Y, Titani K, Holland LZ, Russell SR, Roberts JR, Elder JH, Ruggeri ZM, Zimmerman TS. von Willebrand factor. Reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. J Biol Chem 1986; 261: 381-385
10 Fujimura Y, Holland LZ, Ruggeri ZM, Zimmerman TS. The von Willebrand factor domain-mediated botrocetin-induced binding to glycoprotein lb lies between Val449 and Lys728. Blood 1986; 70: 985-988
11 Fujimura Y, Usami Y, Titani K, Niinomi K, Nishio K, Takase T, Yoshioka A, Fukui H. Studies on anti-von Willebrand factor (vWF) monoclonal antibody NMC-4, which inhibits both ristocetin- and botrocetin-induced vWF binding to platelet glycoprotein Ib. Blood 1991; 77: 113-120
12 Handa M, Titani K, Holland LZ, Roberts JR, Ruggeri ZM. The von Willebrand factor-binding domain of platelet membrane glycoprotein Ib. Characterization by monoclonal antibodies and partial amino acid sequence analysis of proteolytic fragments. J Biol Chem 1986; 261: 12579-12586
13 Nishio K, Fujimura Y, Niinomi K, Takahashi Y, Yoshioka A, Fukui H, Usami Y, Titani K, Ruggeri ZM, Zimmerman TS. Enhanced botrocetin-induced type IIB von Willebrand factor binding to platelet glycoprotein Ib innitiates hyperagglutination of normal platelets. Am J Hematol 1990; 33: 261-266
14 Ruggeri ZM, Pareti FI, Mannucci PM, Ciavarella N, Zimmerman TS. Heightened interaction between platelet and factor VIII/von Willebrand factor in a new subtype of von Willebrand’s disease. N Engl J Med. 1980; 302: 1047-1051
15 Fujimura Y, Titani K, Usami Y, Suzuki M, Oyama R, Matsui T, Fukui H, Sugimoto M, Ruggeri ZM. Isolation and chemical characterization of two structurally and functionally distinct forms of botrocetin, the platelet coagglutinin isolated from the venom of Bothrops jararaca. Biochemistry. 1991; 30: 1957-1964
16 Ey PL, Prowse SJ, Jenkin CR. Isolation of pure IgGl, IgG2a, and IgG2b immunoglobulins from mouse serum using protein A-Sepharose. Immunochemistry 1978; 15: 429-436
17 Fraker DJ, Speck JC. Protein and cell membrane iodinations with sparingly soluble chloroamide, l,3,4,6,-tetrachloro-3a,6a-diphenylglycoluril. Biophys Res Commun 1978; 80: 849-857
18 Yoshioka A, Giddings JC, Thomas JE, Fujimura Y, Bloom AL. Immunoassays of factor IX antigen using monoclonal antibodies. Br J Haematol 1985; 59: 265-275
19 Girma JP, Takahashi Y, Yoshioka A, Diaz J, Meyer D. Ristocetin and botrocetin involve two distinct domains of von Willebrand factor for binding to platelet membrane glycoprotein Ib. Thromb Haemostas 1990; 64: 326-332
20 Fukui H, Yasui M, Takahashi Y, Niinomi K, Takase T, Yoshioka A. Type IIB von Willebrand’s disease: Report on the first case in Japan. Acta Paediatr Jpn 1984; 26: 544-553
21 Sadler JE. von Willebrand factor. J Biol Chem 1991; 266: 22777-22780